Biogen Idec Inc (BIIB) 284.84 $BIIB
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 2.23% Sell Off
Comtex SmarTrend(R) - Fri Nov 13, 4:24PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $283.83 to a high of $293.29. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $290.91 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 284.84 (-6.49)
Biogen Idec Rises 1.30% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 284.84 (-6.49)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.30% Gain
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 284.84 (-6.49)
Buy Amgen's Healthy Dividend, Hold for Its Growth Prescription
at The Street - Tue Nov 10, 6:05AM CST
Amgen's dividend may be just on par with the S&P 500's average, but its forward earnings ratio and price target make it a solid buy-and-hold candidate.
BIIB: 284.84 (-6.49), XBI: 68.27 (-0.05), ALXN: 166.44 (+0.31), AMGN: 151.55 (+0.57)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), IBB: 323.64 (+3.53), REGN: 548.90 (-3.63), CELG: 107.49 (-1.53)
Anavex Presents Meaningless Results in Alzheimer's Drug Study
at The Street - Mon Nov 09, 7:53AM CST
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%," said Dr. Adam Kline, a researcher who reviewed the data.
BIIB: 284.84 (-6.49), AVXL: 4.55 (-0.68)
$5.9 Billion Buyout: 1 Number Underpins Shire's Huge Dyax Bet
Michael Douglass, The Motley Fool - Motley Fool - Sat Nov 07, 6:42AM CST
The number, by the way, is $2 billion. That's how much Shire plc executives think Dyax Corporation 's flagship drug DX-2930 could provide in sales at its peak. If DX-2930 provides $2 billion in peak annual sales, then suddenly Shire's pricey...
BIIB: 284.84 (-6.49), SHPG: 203.58 (-2.36), LLY: 79.55 (-0.31), DYAX: 34.42 (+0.03)
Jim Cramer Loves Bank of America After Friday's Jobs Report
at The Street - Fri Nov 06, 5:01PM CST
Jim Cramer wants to add more Bank of America to the Action Alerts PLUS Portfolio on a pullback.
AGN: 299.63 (-0.41), UA: 87.43 (-4.93), MMM: 155.65 (-0.65), BIIB: 284.84 (-6.49), RCL: 95.50 (-2.22), FEYE: 22.25 (+0.02), CCL: 51.56 (-0.61), FB: 103.95 (-4.07), VFC: 62.05 (-2.56), KHC: 70.77 (-0.13), COLM: 49.08 (+0.33), BAC: 17.20 (-0.17), TWTR: 25.18 (-0.95), MS: 33.93 (-0.30)
Gilead and 2 Biotech Picks Value Investors Will Love
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 4:07PM CST
Don't miss these value biotech stocks for your portfolio.
BIIB: 284.84 (-6.49), ESRX: 82.99 (-1.47), GILD: 102.57 (-1.66), SHPG: 203.58 (-2.36), UTHR: 146.79 (+0.65), AMGN: 151.55 (+0.57), ANIK: 41.92 (+0.13)
Biotech Sees Better-than-Expected Earnings: ETFs in Focus
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 10:22AM CST
Driven by better-than-expected results, ETFs having considerable exposure to these five biotech companies have been surging.
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), ALXN: 166.44 (+0.31), BBH: 120.85 (+0.36), IBB: 323.64 (+3.53), AMGN: 151.55 (+0.57), CELG: 107.49 (-1.53)
Stock Market News for November 06, 2015
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 9:10AM CST
Benchmarks closed modestly lower on Thursday as investors refrained from making big bets ahead of Friday’s nonfarm payroll report
KMI: 23.35 (-0.11), BIIB: 284.84 (-6.49), PCG: 52.26 (-0.53), FB: 103.95 (-4.07), XOM: 78.10 (-1.31), COP: 51.83 (-0.14), AMGN: 151.55 (+0.57), RL: 119.72 (-2.41), SO: 43.95 (+0.06), CELG: 107.49 (-1.53), AEP: 55.06 (-0.26), NEE: 100.43 (-0.30), GILD: 102.57 (-1.66), CVX: 88.68 (-1.18), OXY: 73.51 (+0.37)
Jim Cramer's 'Mad Money' Recap: Why You Should Sink Your Teeth Into FANG
at The Street - Thu Nov 05, 6:48PM CST
Cramer said Facebook, Amazon, Netflix and Alphabet -- the former Google -- represent the best of the best.
WFM: 29.55 (-0.36), MMM: 155.65 (-0.65), BIIB: 284.84 (-6.49), AMZN: 642.35 (-23.25), LMT: 213.16 (-0.42), FEYE: 22.25 (+0.02), GBX: 31.95 (-0.02), FB: 103.95 (-4.07), AGNC: 17.82 (+0.12), DIS: 114.84 (-1.37), PYPL: 34.53 (-1.04), BMY: 64.15 (+0.43), NFLX: 103.65 (-5.27), IRDM: 7.45 (-0.14), AA: 7.99 (+0.17), GILD: 102.57 (-1.66), BOOT: 11.03 (-0.01), NAT: 14.87 (-0.19), GOOGL: 740.07 (-16.46), TWTR: 25.18 (-0.95), PPG: 100.83 (+1.62)
Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 3:20PM CST
Isis Pharmaceuticals (ISIS), which is scheduled to report third-quarter 2015 results on Nov 9, had reported a negative earnings surprise of 14.71% last quarter.
MACK: 9.12 (+0.29), BIIB: 284.84 (-6.49), ISIS: 62.65 (+0.61), AZN: 31.29 (+0.44)
Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax
Arpita Dutt - Zacks Investment Research - Wed Nov 04, 9:41AM CST
Several major biotech companies including AbbVie (ABBV) reported their third quarter results over the last week.
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), RPRX: 1.58 (+0.04), AMGN: 151.55 (+0.57), ABBV: 59.86 (-0.37), DYAX: 34.42 (+0.03), CELG: 107.49 (-1.53)
Is This Drug Going to Be a Big Threat to Biogen and Novartis Next Year?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 04, 9:20AM CST
Source: Sanofi via Facebook. Quarterly sales of Sanofi's oral multiple-sclerosis drug Aubagio have surged by 78.6% in the past year. If that growth continues, then Aubagio could become a big threat to Biogen and Novartis ' competing oral-MS...
BIIB: 284.84 (-6.49), SNY: 42.99 (-0.65), NVS: 86.28 (-0.58)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 284.84 (-6.49), UTHR: 146.79 (+0.65), CTIC: 1.19 (-0.01), CHRS: 26.82 (-0.12), JNJ: 99.88 (-0.39), NPSP: 45.97 (+0.01), IBIO: 0.68 (+0.02), EBS: 36.55 (+0.30), SLXP: 172.96 (+0.15), AMGN: 151.55 (+0.57), SPPI: 5.24 (+0.17), LLY: 79.55 (-0.31), GSK: 39.87 (-0.18), ANIK: 41.92 (+0.13), NVO: 52.93 (-0.57), BAX: 37.57 (+0.11), MRK: 53.03 (unch), NVS: 86.28 (-0.58)
5 Exciting Biotech Stocks to Buy on November Upswing
Zacks Equity Research - Zacks Investment Research - Tue Nov 03, 10:00AM CST
Right now, market sentiment seems to be improving driven by strong earnings, upgraded guidance, product approvals and encouraging pipeline updates.
CYTK: 11.31 (+0.38), BIIB: 284.84 (-6.49), VRTX: 123.05 (+5.75), GILD: 102.57 (-1.66), ALXN: 166.44 (+0.31), AMGN: 151.55 (+0.57), AAVL: 8.08 (+0.30), ANIK: 41.92 (+0.13), REGN: 548.90 (-3.63), XNPT: 6.48 (+0.08), CELG: 107.49 (-1.53)
Global Market Study on Biopharmaceuticals 2015: Asia to Witness Highest Growth by 2020 in the $161 Billion Market
M2 - Tue Nov 03, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/zhsxrk/global_market) has announced the addition of the "Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020" report to their offering. The global biopharmaceuticals market was valued at US$ 161,851.6 Mn in 2014 and is expected to expand at a CAGR of 9.4% to reach US$ 278,232.9 Mn by 2020. North America is the largest market for the biopharmaceuticals. This is due to technological advancements in the region. In terms of types, monoclonal antibodies are the fastest growing segment. In terms of therapeutic application, oncology is the largest segment in the biopharmaceuticals market. Biopharmaceuticals have wide applications in the pharmaceutical industry. The North America biopharmaceuticals market was valued at US$ 64,681.3 Mn in 2014 and is expected to reach US$ 111,598.2 Mn by 2020 at a CAGR of 9.5% over the forecast period. One of the latest trends in the global biopharmaceuticals market is outsourcing, wherein biopharmaceutical companies enter into partnerships with contract manufacturing organizations (CMOs) to produce biopharmaceutical drug substances. This reduces the overall investment to launch a new product in the market and helps gain market access with ease. Pfizer, Inc., F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Sanofi, Amgen Inc., AbbVie Inc., Merck & Co., Inc., Biogen Idec, Bayer AG, Eli Lilly and Company, and Novartis AG are some of the leading players in the global market for biopharmaceuticals. Some of the other players in the biopharmaceuticals market are GlaxoSmithKline Plc, Bristol-Myers Squibb Company, AstraZeneca PLC, and Abbott Laboratories. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Market Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Type Chapter 7 Market Size and Forecast by Therapeutic Application Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - AbbVie Inc. - Abbott Laboratories - Amgen, Inc. - AstraZeneca plc - Bayer AG - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - F. Hoffmann-La Roche, Ltd. - GlaxoSmithKline Plc - Johnson & Johnson Services, Inc. - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/zh...bal_market
ABT: 43.96 (-0.23), BIIB: 284.84 (-6.49), PFE: 33.27 (-0.12), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), BMY: 64.15 (+0.43), GSK: 39.87 (-0.18), JNJ: 99.88 (-0.39), AZN: 31.29 (+0.44), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), NVS: 86.28 (-0.58)
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 2.23% Sell Off
Comtex SmarTrend(R) - Fri Nov 13, 4:24PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $283.83 to a high of $293.29. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $290.91 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 284.84 (-6.49)
Biogen Idec Rises 1.30% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 284.84 (-6.49)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.30% Gain
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 284.84 (-6.49)
Buy Amgen's Healthy Dividend, Hold for Its Growth Prescription
at The Street - Tue Nov 10, 6:05AM CST
Amgen's dividend may be just on par with the S&P 500's average, but its forward earnings ratio and price target make it a solid buy-and-hold candidate.
BIIB: 284.84 (-6.49), XBI: 68.27 (-0.05), ALXN: 166.44 (+0.31), AMGN: 151.55 (+0.57)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), IBB: 323.64 (+3.53), REGN: 548.90 (-3.63), CELG: 107.49 (-1.53)
Anavex Presents Meaningless Results in Alzheimer's Drug Study
at The Street - Mon Nov 09, 7:53AM CST
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%," said Dr. Adam Kline, a researcher who reviewed the data.
BIIB: 284.84 (-6.49), AVXL: 4.55 (-0.68)
$5.9 Billion Buyout: 1 Number Underpins Shire's Huge Dyax Bet
Michael Douglass, The Motley Fool - Motley Fool - Sat Nov 07, 6:42AM CST
The number, by the way, is $2 billion. That's how much Shire plc executives think Dyax Corporation 's flagship drug DX-2930 could provide in sales at its peak. If DX-2930 provides $2 billion in peak annual sales, then suddenly Shire's pricey...
BIIB: 284.84 (-6.49), SHPG: 203.58 (-2.36), LLY: 79.55 (-0.31), DYAX: 34.42 (+0.03)
Jim Cramer Loves Bank of America After Friday's Jobs Report
at The Street - Fri Nov 06, 5:01PM CST
Jim Cramer wants to add more Bank of America to the Action Alerts PLUS Portfolio on a pullback.
AGN: 299.63 (-0.41), UA: 87.43 (-4.93), MMM: 155.65 (-0.65), BIIB: 284.84 (-6.49), RCL: 95.50 (-2.22), FEYE: 22.25 (+0.02), CCL: 51.56 (-0.61), FB: 103.95 (-4.07), VFC: 62.05 (-2.56), KHC: 70.77 (-0.13), COLM: 49.08 (+0.33), BAC: 17.20 (-0.17), TWTR: 25.18 (-0.95), MS: 33.93 (-0.30)
Gilead and 2 Biotech Picks Value Investors Will Love
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 4:07PM CST
Don't miss these value biotech stocks for your portfolio.
BIIB: 284.84 (-6.49), ESRX: 82.99 (-1.47), GILD: 102.57 (-1.66), SHPG: 203.58 (-2.36), UTHR: 146.79 (+0.65), AMGN: 151.55 (+0.57), ANIK: 41.92 (+0.13)
Biotech Sees Better-than-Expected Earnings: ETFs in Focus
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 10:22AM CST
Driven by better-than-expected results, ETFs having considerable exposure to these five biotech companies have been surging.
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), ALXN: 166.44 (+0.31), BBH: 120.85 (+0.36), IBB: 323.64 (+3.53), AMGN: 151.55 (+0.57), CELG: 107.49 (-1.53)
Stock Market News for November 06, 2015
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 9:10AM CST
Benchmarks closed modestly lower on Thursday as investors refrained from making big bets ahead of Friday’s nonfarm payroll report
KMI: 23.35 (-0.11), BIIB: 284.84 (-6.49), PCG: 52.26 (-0.53), FB: 103.95 (-4.07), XOM: 78.10 (-1.31), COP: 51.83 (-0.14), AMGN: 151.55 (+0.57), RL: 119.72 (-2.41), SO: 43.95 (+0.06), CELG: 107.49 (-1.53), AEP: 55.06 (-0.26), NEE: 100.43 (-0.30), GILD: 102.57 (-1.66), CVX: 88.68 (-1.18), OXY: 73.51 (+0.37)
Jim Cramer's 'Mad Money' Recap: Why You Should Sink Your Teeth Into FANG
at The Street - Thu Nov 05, 6:48PM CST
Cramer said Facebook, Amazon, Netflix and Alphabet -- the former Google -- represent the best of the best.
WFM: 29.55 (-0.36), MMM: 155.65 (-0.65), BIIB: 284.84 (-6.49), AMZN: 642.35 (-23.25), LMT: 213.16 (-0.42), FEYE: 22.25 (+0.02), GBX: 31.95 (-0.02), FB: 103.95 (-4.07), AGNC: 17.82 (+0.12), DIS: 114.84 (-1.37), PYPL: 34.53 (-1.04), BMY: 64.15 (+0.43), NFLX: 103.65 (-5.27), IRDM: 7.45 (-0.14), AA: 7.99 (+0.17), GILD: 102.57 (-1.66), BOOT: 11.03 (-0.01), NAT: 14.87 (-0.19), GOOGL: 740.07 (-16.46), TWTR: 25.18 (-0.95), PPG: 100.83 (+1.62)
Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 3:20PM CST
Isis Pharmaceuticals (ISIS), which is scheduled to report third-quarter 2015 results on Nov 9, had reported a negative earnings surprise of 14.71% last quarter.
MACK: 9.12 (+0.29), BIIB: 284.84 (-6.49), ISIS: 62.65 (+0.61), AZN: 31.29 (+0.44)
Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax
Arpita Dutt - Zacks Investment Research - Wed Nov 04, 9:41AM CST
Several major biotech companies including AbbVie (ABBV) reported their third quarter results over the last week.
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), RPRX: 1.58 (+0.04), AMGN: 151.55 (+0.57), ABBV: 59.86 (-0.37), DYAX: 34.42 (+0.03), CELG: 107.49 (-1.53)
Is This Drug Going to Be a Big Threat to Biogen and Novartis Next Year?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 04, 9:20AM CST
Source: Sanofi via Facebook. Quarterly sales of Sanofi's oral multiple-sclerosis drug Aubagio have surged by 78.6% in the past year. If that growth continues, then Aubagio could become a big threat to Biogen and Novartis ' competing oral-MS...
BIIB: 284.84 (-6.49), SNY: 42.99 (-0.65), NVS: 86.28 (-0.58)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 284.84 (-6.49), UTHR: 146.79 (+0.65), CTIC: 1.19 (-0.01), CHRS: 26.82 (-0.12), JNJ: 99.88 (-0.39), NPSP: 45.97 (+0.01), IBIO: 0.68 (+0.02), EBS: 36.55 (+0.30), SLXP: 172.96 (+0.15), AMGN: 151.55 (+0.57), SPPI: 5.24 (+0.17), LLY: 79.55 (-0.31), GSK: 39.87 (-0.18), ANIK: 41.92 (+0.13), NVO: 52.93 (-0.57), BAX: 37.57 (+0.11), MRK: 53.03 (unch), NVS: 86.28 (-0.58)
5 Exciting Biotech Stocks to Buy on November Upswing
Zacks Equity Research - Zacks Investment Research - Tue Nov 03, 10:00AM CST
Right now, market sentiment seems to be improving driven by strong earnings, upgraded guidance, product approvals and encouraging pipeline updates.
CYTK: 11.31 (+0.38), BIIB: 284.84 (-6.49), VRTX: 123.05 (+5.75), GILD: 102.57 (-1.66), ALXN: 166.44 (+0.31), AMGN: 151.55 (+0.57), AAVL: 8.08 (+0.30), ANIK: 41.92 (+0.13), REGN: 548.90 (-3.63), XNPT: 6.48 (+0.08), CELG: 107.49 (-1.53)
Global Market Study on Biopharmaceuticals 2015: Asia to Witness Highest Growth by 2020 in the $161 Billion Market
M2 - Tue Nov 03, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/zhsxrk/global_market) has announced the addition of the "Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020" report to their offering. The global biopharmaceuticals market was valued at US$ 161,851.6 Mn in 2014 and is expected to expand at a CAGR of 9.4% to reach US$ 278,232.9 Mn by 2020. North America is the largest market for the biopharmaceuticals. This is due to technological advancements in the region. In terms of types, monoclonal antibodies are the fastest growing segment. In terms of therapeutic application, oncology is the largest segment in the biopharmaceuticals market. Biopharmaceuticals have wide applications in the pharmaceutical industry. The North America biopharmaceuticals market was valued at US$ 64,681.3 Mn in 2014 and is expected to reach US$ 111,598.2 Mn by 2020 at a CAGR of 9.5% over the forecast period. One of the latest trends in the global biopharmaceuticals market is outsourcing, wherein biopharmaceutical companies enter into partnerships with contract manufacturing organizations (CMOs) to produce biopharmaceutical drug substances. This reduces the overall investment to launch a new product in the market and helps gain market access with ease. Pfizer, Inc., F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Sanofi, Amgen Inc., AbbVie Inc., Merck & Co., Inc., Biogen Idec, Bayer AG, Eli Lilly and Company, and Novartis AG are some of the leading players in the global market for biopharmaceuticals. Some of the other players in the biopharmaceuticals market are GlaxoSmithKline Plc, Bristol-Myers Squibb Company, AstraZeneca PLC, and Abbott Laboratories. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Market Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Type Chapter 7 Market Size and Forecast by Therapeutic Application Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - AbbVie Inc. - Abbott Laboratories - Amgen, Inc. - AstraZeneca plc - Bayer AG - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - F. Hoffmann-La Roche, Ltd. - GlaxoSmithKline Plc - Johnson & Johnson Services, Inc. - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/zh...bal_market
ABT: 43.96 (-0.23), BIIB: 284.84 (-6.49), PFE: 33.27 (-0.12), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), BMY: 64.15 (+0.43), GSK: 39.87 (-0.18), JNJ: 99.88 (-0.39), AZN: 31.29 (+0.44), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), NVS: 86.28 (-0.58)
